[Estradiol valerate/cyproterone acetate in the treatment of climacteric syndrome].
In a prospective study 40 perimenopausal women with climacteric complaints between 45 to 52 years of age were examined. Twenty three (100%) were assigned to treatment with hormonal replacement therapy (Climen fy Schering-estradiol valerate cyproteron acetate) for 6 months. The therapy had to be stopped in 5 women (22%) for side effects. The drug was contraindicated in 17 patients because of non-treated hypertension, varices, hepatopathy and uterine fibroids with repeated metrorrhagia. In 18 patients (78%) Climax score, ALT, AST, bilirubin, total cholesterol, HDL-Chol, LDL-Chol, triglycerides, haemogram, fibrinogen, APTT, Quick test, serum Ca2+ and P2+ and urine C2+ and P2+/24 hours, weight and arterial blood pressure before and after the treatment were examined. The results confirm the benefical effect of Climen on the Climax score (p < 0.0001), total cholesterol (p < 0.01), HDL-Chol (p < 0.05) and LDL-Chol (p < 0.0001). After administration of Climen a significant decrease of P2+ serum concentration was demonstrated. Climen is suitable for treatment of acute climacteric complaints and has benefical effects on lipid metabolism.
Zivný
J
J
II. gynek.-porod. klinika 1. LF UK a VFN, Praha.
Skrenková
J
J
D002979:Climacteric / Q000187:drug effects*; D017373:Cyproterone Acetate / Q000008:administration & dosage* / Q000009:adverse effects; D004338:Drug Combinations; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D008875:Middle Aged; D011446:Prospective Studies
D004338:Drug Combinations; C103294:estradiol valerate, cyproterone acetate drug combination; D017373:Cyproterone Acetate; D004958:Estradiol